Biogen Inc. (NASDAQ: BIIB) Stock Competitors & Peer Comparison
See BIIB's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BIIB and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIIB | $225.71 | +1.60% | 32.3B | 13.79 | $15.84 | N/A |
| LLY | $1,179.27 | -0.79% | 1.1T | 37.15 | $31.49 | +0.57% |
| JNJ | $261.44 | +1.16% | 618B | 23.90 | $10.73 | +2.03% |
| ABBV | $276.47 | +1.88% | 481.4B | 26.74 | $10.19 | +2.47% |
| MRK | $145.60 | +1.97% | 351.7B | 44.36 | $3.21 | +2.32% |
| NVS | $143.75 | +0.33% | 272B | 16.47 | $8.69 | +3.30% |
| AZN | $159.20 | -0.57% | 246.2B | 17.14 | $9.26 | +2.03% |
| AMGN | $414.87 | +0.43% | 219.9B | 18.21 | $22.37 | +2.39% |
| GILD | $151.17 | +2.94% | 182.4B | -377.18 | -$0.39 | +2.16% |
| NVO | $38.64 | +0.99% | 169.4B | 9.49 | $4.02 | +4.66% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
BIIB vs LLY Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while LLY trades at $1,179.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas LLY's P/E ratio is 37.15. In terms of profitability, BIIB's ROE is +0.05%, compared to LLY's ROE of +0.93%. Regarding short-term risk, BIIB is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
BIIB vs JNJ Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, JNJ has a market cap of 618B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while JNJ trades at $261.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas JNJ's P/E ratio is 23.90. In terms of profitability, BIIB's ROE is +0.05%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, BIIB is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
BIIB vs ABBV Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, ABBV has a market cap of 481.4B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while ABBV trades at $276.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas ABBV's P/E ratio is 26.74. In terms of profitability, BIIB's ROE is +0.05%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, BIIB is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
BIIB vs MRK Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, MRK has a market cap of 351.7B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while MRK trades at $145.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas MRK's P/E ratio is 44.36. In terms of profitability, BIIB's ROE is +0.05%, compared to MRK's ROE of +0.07%. Regarding short-term risk, BIIB is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check MRK's competition here
Novartis AG (NYSE: NVS)
BIIB vs NVS Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, NVS has a market cap of 272B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while NVS trades at $143.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas NVS's P/E ratio is 16.47. In terms of profitability, BIIB's ROE is +0.05%, compared to NVS's ROE of +0.30%. Regarding short-term risk, BIIB is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
BIIB vs AZN Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, AZN has a market cap of 246.2B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while AZN trades at $159.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas AZN's P/E ratio is 17.14. In terms of profitability, BIIB's ROE is +0.05%, compared to AZN's ROE of +0.22%. Regarding short-term risk, BIIB is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
BIIB vs AMGN Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, AMGN has a market cap of 219.9B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while AMGN trades at $414.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas AMGN's P/E ratio is 18.21. In terms of profitability, BIIB's ROE is +0.05%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, BIIB is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check AMGN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
BIIB vs GILD Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, GILD has a market cap of 182.4B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while GILD trades at $151.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas GILD's P/E ratio is -377.18. In terms of profitability, BIIB's ROE is +0.05%, compared to GILD's ROE of -0.16%. Regarding short-term risk, BIIB is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check GILD's competition here
Novo Nordisk A/S (NYSE: NVO)
BIIB vs NVO Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, NVO has a market cap of 169.4B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while NVO trades at $38.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas NVO's P/E ratio is 9.49. In terms of profitability, BIIB's ROE is +0.05%, compared to NVO's ROE of +0.59%. Regarding short-term risk, BIIB is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
BIIB vs PFE Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, PFE has a market cap of 158.7B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while PFE trades at $28.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas PFE's P/E ratio is 9.13. In terms of profitability, BIIB's ROE is +0.05%, compared to PFE's ROE of +0.05%. Regarding short-term risk, BIIB is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
BIIB vs BMY Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, BMY has a market cap of 121.7B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while BMY trades at $59.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas BMY's P/E ratio is 10.04. In terms of profitability, BIIB's ROE is +0.05%, compared to BMY's ROE of +0.47%. Regarding short-term risk, BIIB is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check BMY's competition here
Sanofi (NASDAQ: SNY)
BIIB vs SNY Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, SNY has a market cap of 96.6B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while SNY trades at $40.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas SNY's P/E ratio is 8.76. In terms of profitability, BIIB's ROE is +0.05%, compared to SNY's ROE of +0.06%. Regarding short-term risk, BIIB is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check SNY's competition here
GSK plc (NYSE: GSK)
BIIB vs GSK Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, GSK has a market cap of 93.2B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while GSK trades at $46.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas GSK's P/E ratio is 10.05. In terms of profitability, BIIB's ROE is +0.05%, compared to GSK's ROE of +0.24%. Regarding short-term risk, BIIB is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check GSK's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
BIIB vs HZNP Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas HZNP's P/E ratio is 61.86. In terms of profitability, BIIB's ROE is +0.05%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, BIIB is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
BIIB vs GRFS Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, GRFS has a market cap of 6.3B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while GRFS trades at $7.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas GRFS's P/E ratio is 8.51. In terms of profitability, BIIB's ROE is +0.05%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, BIIB is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
BIIB vs OGN Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while OGN trades at $13.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas OGN's P/E ratio is 4.11. In terms of profitability, BIIB's ROE is +0.05%, compared to OGN's ROE of +0.23%. Regarding short-term risk, BIIB is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
BIIB vs AMRN Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, AMRN has a market cap of 248M. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while AMRN trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas AMRN's P/E ratio is -119.90. In terms of profitability, BIIB's ROE is +0.05%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, BIIB is more volatile compared to AMRN. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check AMRN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
BIIB vs MIRA Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, MIRA has a market cap of 29.5M. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while MIRA trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas MIRA's P/E ratio is -0.48. In terms of profitability, BIIB's ROE is +0.05%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, BIIB is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLX)
BIIB vs SCLX Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, SCLX has a market cap of 25.1M. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while SCLX trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas SCLX's P/E ratio is -0.08. In terms of profitability, BIIB's ROE is +0.05%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, BIIB is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
BIIB vs SCLXW Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, SCLXW has a market cap of 21M. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while SCLXW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas SCLXW's P/E ratio is N/A. In terms of profitability, BIIB's ROE is +0.05%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, BIIB is more volatile compared to SCLXW. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
BIIB vs BDSIW Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, BIIB's ROE is +0.05%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, BIIB is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
BIIB vs CRXT Comparison October 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 32.3B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, BIIB is priced at $225.71 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.79, whereas CRXT's P/E ratio is -0.02. In terms of profitability, BIIB's ROE is +0.05%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, BIIB is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check CRXT's competition here